Clinical Trials Browser

Phase 1 × Completed × osimertinib × Clear all

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06525246 2026-03-13

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Phase 1 Completed

78 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

22 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Phase 1 Completed

8 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02157883 2025-11-19

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Phase 1 Completed

39 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05954871 2025-11-13

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Phase 1 Completed

10 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT02520778 2024-08-21

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Completed

27 enrolled

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

NCT03535363 2024-03-13

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Phase 1 Completed

6 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1 Completed

29 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02163733 2024-01-22

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Phase 1 Completed

38 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02923947 2023-11-27

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Phase 1 Completed

16 enrolled

Renal Insufficiency

NCT04959981 2023-07-25

HERKULES-2

Phase 1 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Noonan Syndrome, Thoracic Neoplasms

NCT04541407 2023-05-16

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Phase 1 Completed

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03463525 2023-01-27

ODIN-BM

Phase 1 Completed

4 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Phase 1 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02228369 2021-01-05

BLOOM

Phase 1 Completed

108 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02529995 2020-02-11

AURAChinaPK

Phase 1 Completed

31 enrolled 22 charts

Tumor-Agnostic

Carcinoma

NCT02491944 2016-10-13

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Phase 1 Completed

27 enrolled 21 charts

Tumor-Agnostic

Neoplasms